Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03620357 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
A NA study, sponsored by DexCom.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT03620357: Completed NA study, sponsored by DexCom.
NCT03620357 is a NA study that has completed, run by DexCom. The registered enrollment target is 72 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03620357, a NA study, has completed, sponsored by DexCom.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous glucose monitoring (RT-CGM) and targeted learning modules versus self monitored blood glucose (SMBG) testing.
Primary Outcome
The primary endpoint is defined as change in HbA1c (determined by local lab or POC results).
Interventions
- DEVICE CGM
- DEVICE SMBG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2020-11-04 |
| Phase | NA |
What the finished NCT03620357 record still lists
NCT03620357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which CGM is the first listed.
NCT03620357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03620357 about?
NCT03620357 is a clinical study titled "Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)". A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous glucose monitoring (RT-CGM) and targeted learning modules versus self moni...
What is the current status of trial NCT03620357?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2018-09-05. Estimated completion is 2020-11-04.
What interventions are being tested in trial NCT03620357?
The interventions under investigation include: CGM (DEVICE), SMBG (DEVICE).
Who is sponsoring clinical trial NCT03620357?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03620357's enrollment target sits among peer trials
72 1089th of 2000 higher than 899 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI